Our findings reveal that lidocaine modulated the anti-tumor effects by decreasing IL-10, TGF-β, and IL-35 levels in CD4+CD25+Foxp3+TIICs, decreasing PD-1, and increasing IFN-γ expression in cytotoxic CD8+TIICs through the NF-kb pathway. The gene discussed is FOXP3; the disease is neoplasm.